NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
57 trialsNCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03911557 2025-11-12
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Phase 2 Completed
NCT03581487 2025-11-05
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03026062 2025-09-19
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03212469 2025-05-08
ABIMMUNE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03871036 2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03702179 2024-12-05
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
NCT03204812 2024-10-15
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04156087 2024-09-19
MIMIPAC
University Hospital, Gasthuisberg
Phase 2 Completed
NCT03557918 2024-07-03
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT06446570 2024-06-06
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
Phase 2 Completed
NCT03132467 2024-06-05
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03022500 2024-05-29
Pulmonary sarcomatoid_MEDI4736+Treme
Seoul National University Hospital
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02762006 2024-03-18
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03452332 2023-09-13
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03624231 2023-08-31
DURTRE-RAD
Charite University, Berlin, Germany
Phase 2 Completed
NCT03317457 2023-06-15
MEDISARC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT03202758 2023-02-10
MEDITREME
Centre Georges Francois Leclerc
Phase 1/2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02489448 2022-10-26
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Yale University
Phase 1/2 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed
NCT02563925 2022-08-03
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02626130 2022-07-07
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03122509 2022-07-06
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03122496 2022-06-08
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02536794 2022-05-17
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Northwestern University
Phase 2 Completed
NCT02794883 2022-04-18
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
Phase 2 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT03608865 2022-01-03
Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
Yonsei University
Phase 2 Completed
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02701400 2021-06-22
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT03144778 2021-03-18
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00471887 2020-10-26
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02997995 2020-09-30
ULTIMATE
UNICANCER
Phase 2 Completed